New filler wins FDA approval

January 1, 2005

Santa Barbara, Calif. - The U.S. Food and Drug Administration has approved Inamed Corp.'s Captique, a non-animal-based hyaluronic acid gel to combat facial wrinkles. It is the newest dermal filler to enter the U.S. market.

Santa Barbara, Calif. - The U.S. Food and Drug Administration has approved Inamed Corp.'s Captique, a non-animal-based hyaluronic acid gel to combat facial wrinkles. It is the newest dermal filler to enter the U.S. market.

Captique contains no animal materials, according to its manufacturer, Genzyme Corp. Inamed's first-generation hyaluronic gel, Hylaform, was derived from ground rooster combs.

Captique will compete with Medicis Pharmaceutical Corp.'s hyaluronic gel Restylane. It joins Inamed's Hylaform and Hylaform Plus and Inamed's portfolio of collagen-based wrinkle treatments: Zyderm, Zyplast, CosmoDerm and CosmoPlast.

Inamed is Genzyme's exclusive U.S. marketing and distribution partner for Captique.